Let’s start with the biggest two messages: Roche’s (RHHBY) $5 billion takeover of Spark Therapeutics (ONCE) means that large pharma companies are on a full-fledged buying spree, and that gene therapy, a long-awaited approach to treating hereditary diseases, has made the big time.

The Wall Street Journal reported Saturday that Roche was in talks to buy Spark at a 150 percent premium to the smaller company’s market capitalization Friday. On Monday morning, the two companies announced that Roche would buy Spark for $4.8 billion, or $114.50 per share. Here are five things to keep in mind about this news for anyone who cares about the biotechnology sector.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy